Compugen Ltd Cgen Compugen And Bristolmyers Squibb Clinical Collaboration And Equity Investment Conference Call Transcript | Latest News RSS feed

Compugen Ltd Cgen Compugen And Bristolmyers Squibb Clinical Collaboration And Equity Investment Conference Call Transcript - Latest News


Compugen Ltd. (CGEN) Compugen and Bristol-Myers Squibb Clinical Collaboration and Equity Investment Conference Call (Transcript)

Compugen Ltd. (NASDAQ:CGEN) Bristol-Myers Squibb Clinical Collaboration and Equity Investment Conference Call October 11, 2018 8:30 AM ET Executives Elana Holzman - Investor Relations and Corporate ... read more

Bristol-Myers Squibb and Compugen Announce Clinical Collaboration to Evaluate Therapeutic Regimen in Advanced Solid Tumors

In conjunction with this collaboration, Bristol-Myers Squibb will make a $12 million equity investment ... Call and Webcast Information Compugen management will host a conference call today, Thursday, ... read more

Compugen Reports Third Quarter 2018 Results

HOLON, Israel, Nov. 7, 2018 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer ... Shortly thereafter, we signed a clinical collaboration agreement with Bristol-Myers Squibb, ... read more

Looking for another news?


Compugen Reports Fourth Quarter and Full Year 2018 Results and Announces Corporate Restructuring to Streamline Operations

HOLON, Israel, Feb. 26, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN ... which two clinical trials were initiated for our computationally-discovered immuno-oncology programs, COM701 and BAY ... read more


Pharma Stock Roundup: ABBV, NVS' Humira Biosimilar Agreement, BMY's New Cancer Deal

... Ltd. CGEN announced a new collaboration to study a combination of cancer drugs, Compugen's anti-PVRIG antibody, COM701 and Bristol Myers' PD-1 inhibitor Opdivo in patients with advanced solid ... read more

Bristol-Myers' Collaboration Deal: Accelerating Potential Creation Value For Compugen Ltd.

On October 11th, Compugen Ltd. (NASDAQ: CGEN) announced a new clinical trial collaboration agreement with Bristol-Myers Squibb ("BMS") (NYSE:BMY). The terms included a $12 million equity ... held a ... read more

Bristol-Myers Squibb Company: Bristol-Myers Squibb Reports Third Quarter Financial Results

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the third quarter of 2018 which were highlighted by strong sales and operating performance along with key ... read more

Compugen Reports Third Quarter 2008 Financial Results

Compugen Ltd. (NASDAQ:CGEN) today reported financial results for the third ... usage for calendar year 2009 would be approximately $8 million. A replay of the conference call will be available ... read more

Bristol-Myers Squibb and Compugen Announce Clinical Collaboration to Evaluate Therapeutic Regimen in Advanced Solid Tumors

In conjunction with this collaboration, Bristol-Myers Squibb will make a $12 million equity investment ... Call and Webcast Information Compugen management will host a conference call today, Thursday, ... read more

Compugen Reports Third Quarter 2018 Results

HOLON, Israel, Nov. 7, 2018 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer ... Shortly thereafter, we signed a clinical collaboration agreement with Bristol-Myers Squibb, ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us